Medivir outlicenses the antiviral compound MIV-160 to Guangdong Lantai Viewland Pharmaceutical Co. Ltd
Medivir AB and Guangdong Lantai Viewland Pharmaceutical, China, announced the signing of a licensing agreement on MIV-160 (MV026048), a non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) in late pre-clinical development.
Under the terms of the agreement Guangdong Lantai Viewland Pharmaceutical will make a payment to Medivir by transferring equity. In addition Guangdong Lantai Viewland Pharmaceutical will pay royalties on sales for both oral and topical use of MIV-160. Guangdong Lantai Viewland Pharmaceutical will have responsibility for the development of MIV-160 and commercialization in China (including Hong Kong, Taiwan and Macao). Medivir retains the rights to MIV-160 for all others territories.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.